Kaposi Sarcoma-Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nambiar Puja H, Liang Tao, Labo Nazzarena, Hand Jonathan, Blumberg Emily A, Rana Meenakshi M, Florman Sander, Haydel Brandy, Morris Michele I, Schaenman Joanna, Rodrigues Moreno M S, Werbel William A, Bowring Mary G, Friedman-Moraco Rachel J, Stock Peter, Stosor Valentina, Mehta Shikha, Gilbert Alexander J, Elias Nahel, Mehta Sapna A, Small Catherine B, Haidar Ghady, Malinis Maricar, Pereira Marcus R, Aslam Saima, Wojciechowski David, La Hoz Ricardo, Santos Carlos A Q, Apewokin Senu, Castillo-Lugo Jose A, Ranganna Karthik, Morsheimer Megan, Massie Allan, Segev Dorry L, Miley Wendell, Marshall Vickie, Whitby Denise, Tobian Aaron A A, Durand Christine M
Аннотация
METHODS: Anti-KSHV antibodies were measured in HIV R+ and donors with and without HIV (HIV D-) using a 30-antigen multiplex assay within 3 multicenter kidney transplantation studies. KSHV seropositivity was defined as reactivity to conventional KSHV antigens (≥1 ORF73 or K8.1); reactivity to expanded 5-antigen and 30-antigen panels were also reported. Risk factors were identified using modified Poisson regression. Recipients were monitored for posttransplant anti-KSHV antibody changes and KAD.
RESULTS: KSHV seroprevalence was 40.6% (143/352) among HIV R+, 25.2% (33/131) among HIV D+, and 7.5% (4/53) among HIV D-. In the multivariable model, only men who have sex with men (MSM) status was associated with KSHV seropositivity (relative risk, 1.51 [95% confidence interval {CI}, 1.07-2.14] in recipients and 2.39 [95% CI, 1.03-5.53] in donors). Among 418 HIV R+ (215 HIV D+/R+, 203 HIV D-/R+), there were 5 KAD cases (incidence, 0.63 cases/100 person-years [95% CI, .26-1.52]): 3 skin-only Kaposi sarcoma (KS), 1 multicentric Castleman disease, and 1 allograft KS. The allograft KS occurred in a female HIV D+/R+ and was likely donor derived. Remaining KAD cases occurred in male HIV D-/R+ and were likely recipient KSHV reactivation or acquisition.
CONCLUSIONS: In the United States, KSHV seroprevalence in donors and recipients with HIV was high, particularly among MSM. Reassuringly, KSHV-associated disease was rare and primarily attributed to recipient rather than donor-derived KSHV.